In kids with immune-mediated inflammatory diseases, multitargeted therapy may benefit some, with over half achieving ...
Survival in myeloma is clearly being prolonged,” says Mikhael. “Whereas historically, we saw a greater impact in younger ...
A DR5-mediated apoptotic strategy combined with irinotecan/temozolomide achieved a 64.5% ORR and 87.1% DCR in ...
Per-protocol survival improved versus earlier cutoffs, with 35% alive beyond 30 months and 13% beyond 50 months after two ...
Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Laboratorio LKM S.A., and its Mexican affiliate, ...
The "Checkpoint Inhibitor Refractory Cancer Drugs Market -- Growth, Share, Opportunities & Competitive Analysis, 2025 -- 2032" report has been added to the Credence Research Inc. offering. The global ...
Following a second injection at eight weeks, the patient maintained stable vision and remained dry at 12 weeks, allowing for ...
Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with ...
Selected for oral presentation at Clinical Trials Mini SymposiumSOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) ...
Recent advances in cancer treatment are transforming the outlook for patients with lymphoma, offering renewed hope where options were once limited. According to Dr. Rahul Bhargava, one of India’s ...
In this exclusive MedPage Today video, Jonathan Bernstein, MD, of the University of Cincinnati College of Medicine, discusses emerging data on barzolvolimab, an investigational humanized monoclonal ...
HONG KONG SAR, China and SHENZHEN, China and CAMBRIDGE, Mass., March 17, 2026 /PRNewswire/ -- Innorna, a clinical--stage biotech company advancing RNA medicines, today announced that the U.S. Food and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results